Abstract
Breast cancer is the second-leading cause of cancer death among women in the United States, alone. Many papers throughout the past and current medical literature have shown it is strongly associated with the reproductive axis and the growth hormone axis. Ghrelin is a pleiotropic 28-aminoacidic hormone and an integrated component of the GH axis, which is implicated in breast cancer risk factors. There has never been published a systematic review about ghrelin, its receptor and gene and their relation to breast cancer till this day, to our knowledge. The main goal of this systematic review is to explore the aforementioned relationship in perspective to new therapeutic targets. A systematic review of relevant studies by searching the PubMed and the SciVerse Scopus databases was performed retrieving four (4) experimental studies, three (3) cohort and one (1) case-control study, which were included in the present systematic review, out of 63 papers. Ghrelin is definitely an auspicious candidate molecule for breast cancer prevention, detection and therapy. Future studies should be encouraged to investigate ghrelin axis on breast cancer pathogenesis and/or tumorigenesis, which hopefully would give results in difficult breast cancer cases, such as in reproductive females.
Keywords: Ghrelin, breast cancer, novel therapeutic targets, hormonal levels, pathophysiologic mechanisms, 28-aminoacidic hormone, mammography, progesterone, oestrogen, pathogenesis
Current Signal Transduction Therapy
Title:The Role of Ghrelin Signals in Breast Cancer- A Systematic Review
Volume: 7 Issue: 3
Author(s): Charikleia Stefanaki, Filippos-Paschalis Rorris and Michael Stamatakos
Affiliation:
Keywords: Ghrelin, breast cancer, novel therapeutic targets, hormonal levels, pathophysiologic mechanisms, 28-aminoacidic hormone, mammography, progesterone, oestrogen, pathogenesis
Abstract: Breast cancer is the second-leading cause of cancer death among women in the United States, alone. Many papers throughout the past and current medical literature have shown it is strongly associated with the reproductive axis and the growth hormone axis. Ghrelin is a pleiotropic 28-aminoacidic hormone and an integrated component of the GH axis, which is implicated in breast cancer risk factors. There has never been published a systematic review about ghrelin, its receptor and gene and their relation to breast cancer till this day, to our knowledge. The main goal of this systematic review is to explore the aforementioned relationship in perspective to new therapeutic targets. A systematic review of relevant studies by searching the PubMed and the SciVerse Scopus databases was performed retrieving four (4) experimental studies, three (3) cohort and one (1) case-control study, which were included in the present systematic review, out of 63 papers. Ghrelin is definitely an auspicious candidate molecule for breast cancer prevention, detection and therapy. Future studies should be encouraged to investigate ghrelin axis on breast cancer pathogenesis and/or tumorigenesis, which hopefully would give results in difficult breast cancer cases, such as in reproductive females.
Export Options
About this article
Cite this article as:
Stefanaki Charikleia, Rorris Filippos-Paschalis and Stamatakos Michael, The Role of Ghrelin Signals in Breast Cancer- A Systematic Review, Current Signal Transduction Therapy 2012; 7 (3) . https://dx.doi.org/10.2174/157436212802481547
DOI https://dx.doi.org/10.2174/157436212802481547 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pro-Inflammatory Mechanisms in Diabetic Neuropathy: Focus on the Nuclear Factor Kappa B Pathway
Current Drug Targets Anti-Inflammatory Drugs in Psychiatry
Inflammation & Allergy - Drug Targets (Discontinued) Glioblastoma Targeted Gene Therapy Based on pEGFP/p53-Loaded Superparamagnetic Iron Oxide Nanoparticles
Current Gene Therapy The Antimalarial Drug Pyronaridine Inhibits Topoisomerase II in Breast Cancer Cells and Hinders Tumor Progression In Vivo
Clinical Cancer Drugs Radionuclide Liver Cancer Therapies: From Concept to Current Clinical Status
Anti-Cancer Agents in Medicinal Chemistry Aurora A and B Kinases - Targets of Novel Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery Anti-VEGF Anticancer Drugs: Mind the Hypertension
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Targeting Nanoparticles as Drug Delivery Systems for Cancer Treatment
Current Nanoscience Modulators of Acetylcholinesterase Activity: From Alzheimer's Disease to Anti-Cancer Drugs
Current Medicinal Chemistry Peroxisome Proliferator-Activated Receptors and their Ligands in Cancer Drug- Resistance: Opportunity or Challenge
Anti-Cancer Agents in Medicinal Chemistry The Inverse Relationship Between Cancer and Alzheimer's Disease: A Possible Mechanism
Current Alzheimer Research Cytotoxic and Antibiotic Potential of Secondary Metabolites from the Lichen <i>Umbilicaria muhlenbergii</i>
Current Pharmaceutical Biotechnology Nitric Oxide and Cancer Therapy: The Emperor has NO Clothes
Current Pharmaceutical Design RAGE: A Multi-Ligand Receptor Unveiling Novel Insights in Health and Disease
Current Medicinal Chemistry Smart Synthetic Polymer Nanocarriers for Controlled and Site-Specific Drug Delivery
Current Topics in Medicinal Chemistry Chitosan Surface-Modified PLGA Nanoparticles: Preparation, Characterization, and Evaluation of their In Vitro Drug-Release Behaviors and Cytotoxicities
Current Nanoscience Liposomes and Lipid Envelope-Type Systems for Systemic siRNA Delivery
Current Pharmaceutical Design The proNGF-p75NTR-Sortilin Signalling Complex as New Target for the Therapeutic Treatment of Parkinsons Disease
CNS & Neurological Disorders - Drug Targets HSP60 as a Drug Target
Current Pharmaceutical Design miR-221/222 Confers Radioresistance in Glioblastoma Cells Through Activating Akt Independent of PTEN Status
Current Molecular Medicine